AstraZeneca Stops Lung Cancer Trial on Volrustomig

AstraZeneca has discontinued its clinical trial of experimental drug volrustomig after determining it failed to outperform existing lung cancer treatments. However, the company reported positive results from two separate late-stage trials that bolster its cancer portfolio, particularly one combining Tagrisso with Orpathys for non-small cell lung cancer patients.